Expertise in
13
conditions

Dr. Syed K. Lateef

Gastroenterology
821 Oakley Seaver Dr, 
Clermont, FL 
On Staff At
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Expertise in
13
conditions
821 Oakley Seaver Dr, 
Clermont, FL 

Overview

Syed Lateef is a Gastroenterologist in Clermont, Florida. Dr. Lateef is highly rated in 13 conditions, according to our data. His top areas of expertise are Chronic Erosive Gastritis, Childhood Volvulus, Portal Hypertension, and Indigestion. Dr. Lateef is currently accepting new patients.

His clinical research consists of participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution

Gandhi Medical College-Osmania Univ

Residency

Our Lady of Mercy Medical Center , Internal Medicine

Specialties

Gastroenterology

Licenses

Internal Medicine in FL

Fellowships

Mount Sinai School of Medicine of New York University , Internal Medicine

Hospital Affiliations

Osceola Regional Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Freedom Health
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Health First
  • HMO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

South Lake Gastroenterology Inc
821 Oakley Seaver Dr, Clermont, FL 34711
Other Locations
South Lake Gastroenterology Inc
201 Mohawk Rd Ste 100, Minneola, FL 34715
Gastroenterology Associates Of Osceola Pa
710 Oak Commons Blvd, Kissimmee, FL 34741
Gastroenterology Associates Of Osceola Pa
2900 17th St Ste 4, Saint Cloud, FL 34769

Additional Areas of Focus

Dr. Lateef has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Randomized, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of Vedolizumab Intravenous as Maintenance Therapy in Pediatric Subjects With Moderately to Severely Active Crohn's Disease Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy
A Randomized, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of Vedolizumab Intravenous as Maintenance Therapy in Pediatric Subjects With Moderately to Severely Active Crohn's Disease Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy
Enrollment Status: Recruiting
Publish Date: October 20, 2025
Intervention Type: Drug
Study Drug: Vedolizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients With Crohn's Disease
A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients With Crohn's Disease
Enrollment Status: Active_not_recruiting
Publish Date: December 15, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Randomized, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of Vedolizumab Intravenous as Maintenance Therapy in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy
A Randomized, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of Vedolizumab Intravenous as Maintenance Therapy in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy
Enrollment Status: Completed
Publish Date: October 01, 2025
Intervention Type: Drug
Study Drug: Vedolizumab
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
Enrollment Status: Completed
Publish Date: January 24, 2025
Intervention Type: Drug
Study Drug: Tirzepatide
Study Phase: Phase 2
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
Enrollment Status: Completed
Publish Date: December 27, 2024
Intervention Type: Drug
Study Drugs: Mirikizumab, Ustekinumab
Study Phase: Phase 3
An Adaptive Phase 2, Randomized, Double Blind, Placebo Controlled Study of LY3471851 (NKTR 358) in Patients With Moderately to Severely Active Ulcerative Colitis
An Adaptive Phase 2, Randomized, Double Blind, Placebo Controlled Study of LY3471851 (NKTR 358) in Patients With Moderately to Severely Active Ulcerative Colitis
Enrollment Status: Terminated
Publish Date: September 05, 2023
Intervention Type: Drug
Study Drug: LY3471851
Study Phase: Phase 2
View 5 Less Clinical Trials
Similar Doctors
Expertise in
32
conditions
Dr. Shyam Varadarajulu
Gastroenterology
Expertise in
32
conditions
Dr. Shyam Varadarajulu
Gastroenterology

AdventHealth Orlando

601 E Rollins St, 
Orlando, FL 
 (21.8 miles away)
407-303-2570
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Shyam Varadarajulu is a Gastroenterologist in Orlando, Florida. Dr. Varadarajulu is highly rated in 32 conditions, according to our data. His top areas of expertise are Hereditary Pancreatitis, Pancreatic Pseudocyst, Acute Pancreatitis, Endoscopy, and Pancreatectomy.

Udayakumar Navaneethan
Expertise in
37
conditions
Dr. Udayakumar Navaneethan
Gastroenterology
Expertise in
37
conditions
Dr. Udayakumar Navaneethan
Gastroenterology

AdventHealth Orlando

601 E Rollins St, 
Orlando, FL 
 (21.8 miles away)
407-303-9921
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Udayakumar Navaneethan is a Gastroenterologist in Orlando, Florida. Dr. Navaneethan is highly rated in 37 conditions, according to our data. His top areas of expertise are Sclerosing Cholangitis, Cholangitis, Ulcerative Colitis, Endoscopy, and Colonoscopy.

Expertise in
33
conditions
Dr. Muhammad Hasan
Gastroenterology
Expertise in
33
conditions
Dr. Muhammad Hasan
Gastroenterology

AdventHealth Medical Group Center For Interventional Endoscopy

601 E Rollins St, 
Orlando, FL 
 (21.8 miles away)
754-255-6610
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Muhammad Hasan is a Gastroenterologist in Orlando, Florida. Dr. Hasan is highly rated in 33 conditions, according to our data. His top areas of expertise are Bile Duct Obstruction, Hereditary Pancreatitis, Cholestasis, Endoscopy, and Gastric Bypass. Dr. Hasan is currently accepting new patients.

Frequently Asked Questions about Dr. Syed K. Lateef

How do I make an appointment with Dr. Syed K. Lateef?

You can book an appointment with Dr. Syed K. Lateef by calling their office at 352-242-1665. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Syed K. Lateef a top-rated expert for Chronic Erosive Gastritis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Syed K. Lateef is classified as an Advanced expert for Chronic Erosive Gastritis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Syed K. Lateef specialize in?

While Dr. Syed K. Lateef is a Gastroenterology, they have specific expertise in Chronic Erosive Gastritis, Childhood Volvulus, and Portal Hypertension. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Gastroenterology.

Does Dr. Syed K. Lateef accept my insurance?

Dr. Syed K. Lateef accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 352-242-1665 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lateef's expertise for a condition
ConditionClose
      View All 13 Advanced Conditions
      View All 54 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile